US biotech firm Biomarin ended the second quarter with a revenue growth of 17 percent compared to the same period last year. The result was USD 501.7m.
Revenue for the first half year totaled USD 987.7m, a 6 percent increase compared to the first half of 2020.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.